Adverse Drug Reaction Seen With Repaglinide and Gemfibrozil

September 29, 2003

Medscape Staff Report

Sept. 29, 2003 — The U.S. Food and Drug Administration announced today that an adverse drug reaction has been seen during co-administration of repaglinide (Prandin), a short-acting insulin secretagogue, and gemfibrozil (Lopid), a lipid-lowering agent used to treat dyslipidemia.

A study that evaluated the co-administration of gemfibrozil with repaglinide in healthy subjects found a significant increase in repaglinide blood levels. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. Co-administration of itraconazole (Sporanox), an antifungal, with gemfibrozil and repaglinide further increased such effects.

According to the "Drug-Drug Interactions" section of repaglinide's updated labeling, co-administration of both gemfibrozil and itraconazole with repaglinide resulted in a 19-fold higher repaglinide area under the curve and prolonged repaglinide half-life to 6.1 hours. Plasma repaglinide concentration at 7 hours increased 28.6-fold with gemfibrozil co-administration and 70.4-fold with the gemfibrozil-itraconazole combination.

For patients already receiving repaglinide and gemfibrozil, blood glucose levels should be monitored and repaglinide dose adjustment may be needed, recommended a letter to healthcare professionals from Novo-Nordisk, the maker of Prandin.

Reviewed by Gary D. Vogin, MD


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.